Inclusion Criteria:

- Histologically confirmed stage IV kidney clear cell carcinoma.

- Confirmed progressive disease after receiving a previous systemic therapy, including
at least one line of standard of care.

- Measurable disease

- Age >18 years.

- Life expectancy of greater than 3 months.

- At least 5 years free of any other cancer(s). Basal cell carcinoma, provided that is
neither infiltrating nor sclerosing and carcinoma in situ of the cervix, is
acceptable.

- ECOG performance status 2 or lower (Karnofsky 60%).

- Normal organ and marrow function

- Adequate contraception prior to study entry and for the duration of study
participation.

- Ability to understand and have the willingness to sign a written informed consent
document.

- Ability to receive central vein access catheter and manage an infusion pump.

- Women of child bearing potential must have a negative serum pregnancy test.

Exclusion Criteria:

- Anti-cancer therapy within 4 weeks prior to entering the study

- Investigational agents less than 30 days prior to enrollment in the study.

- Known brain metastases

- History of allergic reactions attributed to compounds of similar composition to
CAP-232.

- Past or current cancer other than kidney cancer, except for: Curatively treated
non-melanoma skin cancer, In situ carcinoma of the cervix, Other cancer curatively
treated and with no evidence of disease for at least 5 years

- Uncontrolled intercurrent illness /social situations that would limit compliance with
study requirements.

- Breastfeeding

- Patients previously enrolled into this study and subsequently withdrawn